Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SAB Biotherapeutics Inc (SABSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: SABSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio 0.09 | 1Y Target Price - |
Price to earnings Ratio 0.09 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.55 | 52 Weeks Range 0.02 - 0.15 | Updated Date 06/29/2025 |
52 Weeks Range 0.02 - 0.15 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -11193.25% |
Management Effectiveness
Return on Assets (TTM) -48.28% | Return on Equity (TTM) -92.35% |
Valuation
Trailing PE 0.09 | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6435987 |
Shares Outstanding - | Shares Floating 6435987 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
SAB Biotherapeutics Inc
Company Overview
History and Background
SAB Biotherapeutics, Inc. is a biopharmaceutical company developing novel immunotherapies. Founded in 2014, it focuses on using DiversitAb platform to produce human polyclonal antibodies without human donors.
Core Business Areas
- Therapeutic Development: Developing immunotherapies for infectious diseases, autoimmune diseases, and cancer using its DiversitAbu2122 platform.
- Contract Manufacturing: Provides contract development and manufacturing services to other companies for antibody-based therapeutics.
Leadership and Structure
Eddie J. Sullivan, PhD is the co-founder, President and CEO. The company has a board of directors and various functional departments including R&D, Manufacturing, and Commercial.
Top Products and Market Share
Key Offerings
- SAB-185 (COVID-19 Therapy): SAB-185 was a lead therapeutic candidate for treating COVID-19, now discontinued in favor of new targets. Competitors in the COVID-19 treatment space include Pfizer (Paxlovid), Merck (Molnupiravir), and Regeneron (Ronapreve).
- DiversitAb Platform: A proprietary platform for producing fully-human polyclonal antibodies from transchromosomic cattle. Market share for the platform itself is difficult to define, but potential competitors are companies developing similar antibody platforms or those offering traditional antibody development services.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and long development timelines. Antibody-based therapeutics are a major growth area.
Positioning
SAB Biotherapeutics is positioned as an innovator in antibody therapeutics, particularly focusing on polyclonal antibodies produced through its DiversitAbu2122 platform. They compete with companies developing monoclonal and polyclonal antibodies, and platform technologies.
Total Addressable Market (TAM)
The total addressable market for antibody therapeutics is estimated to be in the hundreds of billions of dollars annually. SAB Biotherapeutics aims to capture a portion of this market with its innovative platform and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary DiversitAbu2122 platform
- Ability to produce fully-human polyclonal antibodies
- Potential for rapid response to emerging infectious diseases
- Experienced management team
Weaknesses
- Limited number of products in clinical trials
- Reliance on a single platform technology
- High cash burn rate
- Dilution of stock
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased demand for antibody-based therapies
- Government funding for pandemic preparedness
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Technological advancements in alternative therapeutic modalities
Competitors and Market Share
Key Competitors
- LLY
- AZN
- REGN
Competitive Landscape
SAB Biotherapeutics faces intense competition from large pharmaceutical companies with greater resources and established market presence. Its DiversitAb platform offers a potential competitive advantage, but the company needs to demonstrate clinical efficacy and secure commercial partnerships.
Growth Trajectory and Initiatives
Historical Growth: Growth was primarily driven by government contracts and research grants. The stock has been delisted from NASDAQ.
Future Projections: Future growth is highly uncertain given the company's financial position and its delisted status. Any projections would be speculative without more recent information.
Recent Initiatives: Recent initiatives are not publicly available due to the company's current status. Historically initiatives were centered around advancing its pipeline of antibody therapeutics and securing partnerships.
Summary
SAB Biotherapeutics has an innovative antibody platform but faces significant challenges. A strength is its DiversitAb platform for polyclonal antibody generation. A weakness is its delisted status and unprofitability. It needs to secure further funding and demonstrate clinical success. The future of the company appears uncertain, especially now that it is delisted.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (historical)
- Company Website (historical)
- Industry Reports
- News Articles
- Delisting information
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and may not be complete or accurate. The delisted status of SAB Biotherapeutics significantly impacts the reliability and completeness of available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SAB Biotherapeutics Inc
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-02-09 | CEO & Executive Chairman Mr. Samuel J. Reich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | |
Full time employees 63 | |||
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.